.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,348,361

« Back to Dashboard
Patent 7,348,361 protects CYSVIEW KIT and is included in one NDA.

This patent has ten patent family members in eight countries.

Summary for Patent: 7,348,361

Title:Solution for diagnosing or treating tissue pathologies
Abstract:The invention concerns a 5-aminolevulinic acid ester (E-ALA) solution for producing a pharmaceutical preparation useful for diagnosing and/or treating tissue and/or cell pathologies by local radiation exposure using radiation emitted by a light source energy followed, in the case diagnosis, by detection of fluorescent protoporphyrin IX (Pp1X). The E-ALA concentration in the solution is less than 1% and ranges between 0.01% and 0.5%. The low E-ALA concentration in the solution increases Pp1X synthesis and homogenises its distribution in the cell layers while highly reducing the secondary toxicity for the treated cells.
Inventor(s): Marti; Alexandre (Geneva, CH), Lange; Norbert (Lausanne, CH), Zellweger; Matthieu (Lausanne, CH), Wagnieres; Georges (Morges, CH), Van Den Bergh; Hubert (Goumoens-la-Ville, CH), Jichlinski; Patrice (Le Mont-sur-Lausanne, CH), Kucera; Pavel (Lausanne, CH)
Assignee: Ecole Polytechnique Federale de Lausanne (Lausanne, CH)
Application Number:09/673,871
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Formulation;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 5th percentile
Forward Citations: 1st percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Photocure Asa
CYSVIEW KIT
hexaminolevulinate hydrochloride
FOR SOLUTION;INTRAVESICAL022555-001May 28, 2010RXYes7,348,361► subscribeY DETECTION OF NON-MUSCLE INVASIVE PAPILLARY CANCER OF THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,348,361

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France98 05425Apr 22, 1998
PCT Information
PCT FiledApril 22, 1999PCT Application Number:PCT/CH99/00163
PCT Publication Date:October 28, 1999PCT Publication Number: WO99/53962

International Patent Family for Patent: 7,348,361

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan2010163445► subscribe
Japan4630395► subscribe
Japan2002512205► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc